The Scientist spoke to Mount Desert Island Biological Laboratory’s Jim Strickland about the institute’s new MDI Bioscience initiative to perform more drug testing and development in nonmammalian models.

Levels of pharmaceuticals considered unsafe for aquatic organisms were found at more than one-quarter of sampling sites.

The steroid’s exceptional performance in early results from the RECOVERY clinical trial in the United Kingdom is a rational outcome of the drug’s anti-inflammatory effects, experts say.

The sponsors of upwards of 1,000 clinical trials may be forced to publish data that have gone unpublished over a 10-year period.

The widely expected move comes months after the companies scrapped trials of another Alzheimer’s drug.

The drug promotes and sustains brain cell connectivity in mice, reversing the effects of chronic stress.

A prototype in-vein device would collect toxic medications before they reach healthy tissues.

This year’s winners are C. David Allis, Michael Grunstein, John Glen, and Joan Steitz.

As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.

Multidrug combinations lead to better results for cancer patients, but efficiently identifying them is proving difficult.

Researchers use several different strategies to deliver a one-two punch.

The company’s recent effort to find new treatments for Alzheimer’s ended in disappointment.

The Good Pharma Scorecard finds some big pharmaceutical companies are meeting legal standards for disclosing results—but many studies still go unreported.